Drug Trial Radar · NCT06592768
A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma
Last checked: Nov 19, 2026Latest source record: Sep 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
17
Actual
Start
Nov 26, 2024
Primary completion
Aug 11, 2025
Study completion Aug 11, 2025
Sponsor
- Lead sponsor
- Jasper Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study JSP-CP-012 is designed as a proof of concept, parallel-group, single dose, double blind, placebo-controlled study using an allergen challenge model. A single dose proof of concept approach at a dose level shown to be biologically active should inform the impact of briquilimab on allergic asthma as compared to placebo while minimizing exposure to participants, in a new indication.
Conditions
- Allergic Asthma
Interventions
BriquilimabDrug
Subcutaneous Administration
Placebo ComparatorOther
Subcutaneous Administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and tolerability of briquilimab in mild-to-moderate asthmatic participantsTime frame: From signing the informed consent form (ICF) through end of trial (EOT) visit (up to 4.5 months)
- To compare the effect of treatment with briquilimab vs placebo on the allergen-induced LARTime frame: 3-7 hours after allergen challenge between Briquilimab and Placebo at week 6
- To compare the effect of treatment with briquilimab vs placebo on the allergen-induced LARTime frame: 3-7 hours after allergen challenge between Briquilimab and Placebo at week 6
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
University of Calgary
Calgary, Alberta, Canada
University of Alberta
Edmonton, Alberta, Canada
University of British Columbia
Vancouver, British Columbia, Canada
McMaster University
Hamilton, Ontario, Canada
University of Laval
Québec, Quebec, Canada
University of Saskatchewan
Saskatoon, Saskatchewan, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.